Second‑line triple therapy in failures with vonoprazan‑based triple therapy for eradication of Helicobacter pylori

Mori,Naoyoshi; Nishiura,Yuuki; Suga,Daisuke; Moritani,Isao; Yamanaka,Yutaka; Ooya,Yumi; Inoue,Hidekazu; Takase,Koujirou; Hioki,Masato; Shiraki,Katsuya

doi:10.3892/br.2018.1111

Second‑line triple therapy in failures with vonoprazan‑based triple therapy for eradication of Helicobacter pylori

Authors:
- Naoyoshi Mori
- Yuuki Nishiura
- Daisuke Suga
- Isao Moritani
- Yutaka Yamanaka
- Yumi Ooya
- Hidekazu Inoue
- Koujirou Takase
- Masato Hioki
- Katsuya Shiraki
View Affiliations

Affiliations: Department of Pharmacy, Mie Prefectural General Medical Center, Yokkaichi, Mie 510‑8561, Japan, Department of Gastroenterology, Mie Prefectural General Medical Center, Yokkaichi, Mie 510‑8561, Japan
Published online on: June 11, 2018 https://doi.org/10.3892/br.2018.1111
Pages: 169-174

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric acid inhibition during treatment is important for the eradication of Helicobacter pylori (H. pylori) infection. A novel potassium‑competitive acid blocker, vonoprazan (VPZ), has been demonstrated to achieve high eradication rates; however, the efficacy of second‑line treatment in failures of VPZ‑based triple therapy has not been well studied. The aim of the current study was to determine the efficacy of VPZ in a first‑line regimen for H. pylori eradication, and the efficacy of a second‑line regimen using metronidazole (MTZ) in failures with the first‑line regimen. Of 580 subjects enrolled in the study, 524 patients completed first‑line treatment (275 patients who received VPZ and 249 patients who received LPZ). First‑line regimens consisted of a combination of clarithromycin (CAM) 200 or 400 mg twice a day, amoxicillin (AMPC) 750 mg twice a day, and either LPZ 30 mg or VPZ 20 mg twice a day, administered orally for 7 days. CAM and VPZ/LPZ were replaced with metronidazole (MTZ) 250 mg and rabeprazole 10 mg in the second‑line regimens. The eradication of H. pylori was assessed by the H. pylori stool antigen test. The overall first‑line eradication rate with VPZ was significantly higher than that with LPZ [91.0% (250/275) vs. 84.7% (211/249), respectively, P=0.030]. The dose of CAM (400 vs. 800 mg) did not affect the eradication rate in either the VPZ or LPZ regimens. The overall eradication rates of the second‑line regimens with MTZ did not differ significantly between the VPZ‑failure and LPZ‑failure groups [87.0% (20/23) vs. 87.9% (29/33), respectively, P=0.700]. Therefore, VPZ was significantly more effective than LPZ for first‑line treatment. In patients with failure of first‑line eradication therapy, successful results of second‑line eradication therapy did not differ between the VPZ‑ and LPZ‑failure groups. In conclusion, VPZ‑based triple therapy should be recommended for eradication of H. pylori.

View Figures

View References

1	Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A and Asaka M: Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study. Gut. 65:1439–1446. 2016. View Article : Google Scholar : PubMed/NCBI
2	McColl KE: Clinical practice. Helicobacter pylori infection. N Engl J Med. 362:1597–1604. 2010. View Article : Google Scholar : PubMed/NCBI
3	Tsujimae M, Yamashita H, Hashimura H, Kano C, Shimoyama K, Kanamori A, Matsumoto K, Koizumi A, Momose K, Eguchi T, et al: A comparative study of a new class of gastric acid suppressant agent named vonoprazan versus esomeprazole for the eradication of Helicobacter pylori. Digestion. 94:240–246. 2016. View Article : Google Scholar : PubMed/NCBI
4	Okamura T, Suga T, Nagaya T, Arakura N, Matsumoto T, Nakayama Y and Tanaka E: Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: A multi-generational comparison. Helicobacter. 19:214–220. 2014. View Article : Google Scholar : PubMed/NCBI
5	Graham DY and Shiotani A: New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 5:321–331. 2008. View Article : Google Scholar : PubMed/NCBI
6	Hunt RH: pH and Hp-gastric acid secretion and Helicobacter pylori: Implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 88:481–483. 1993.PubMed/NCBI
7	Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K and Hasegawa S: Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: A phase 1, open-label, randomized, crossover study. Adv Ther. 33:1519–1535. 2016. View Article : Google Scholar : PubMed/NCBI
8	Jung YS, Kim EH and Park CH: Systematic review with meta-analysis: The efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 46:106–114. 2017. View Article : Google Scholar : PubMed/NCBI
9	Tanabe H, Ando K, Sato K, Ito T, Goto M, Sato T, Fujinaga A, Kawamoto T, Utsumi T, Yanagawa N, et al: Efficacy of vonoprazan-based triple therapy for Helicobacter pylori eradication: A multicenter study and a review of the literature. Dig Dis Sci. 64:3069–3076. 2017. View Article : Google Scholar
10	International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline: Guideline for good clinical Practice E6 (R1). https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf
11	National Cancer Institute, National Institutes of Health, US Department of Health and Human Services: Common Terminology criteria for adverse events (CTCAE). Version 4.0.
12	Grayson ML, Eliopoulos GM, Ferraro MJ and Moellering RC Jr: Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis. 8:888–889. 1989. View Article : Google Scholar : PubMed/NCBI
13	Sachs G, Meyer-Rosberg K, Scott DR and Melchers K: Acid, protons and Helicobacter pylori. Yale J Biol Med. 69:301–316. 1996.PubMed/NCBI
14	Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O and Sachs G: Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 339:412–420. 2011. View Article : Google Scholar : PubMed/NCBI
15	Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, Hirase K, Kajino M and Inatomi N: 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 335:231–238. 2010. View Article : Google Scholar : PubMed/NCBI
16	Matsukawa J, Hori Y, Nishida H, Kajino M and Inatomi N: A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 81:1145–1151. 2011. View Article : Google Scholar : PubMed/NCBI
17	Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M and Inatomi N: A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 337:797–804. 2011. View Article : Google Scholar : PubMed/NCBI
18	Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T and Shiramoto M: Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study. Aliment Pharmacol Ther. 42:719–730. 2015. View Article : Google Scholar : PubMed/NCBI
19	Ashida K, Sakurai Y, Nishimura A, Kudou K, Hiramatsu N, Umegaki E, Iwakiri K and Chiba T: Randomised clinical trial: A dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 42:685–695. 2015. View Article : Google Scholar : PubMed/NCBI
20	Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, Umegaki E and Iwakiri K: Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 43:240–251. 2016. View Article : Google Scholar : PubMed/NCBI
21	Miwa H, Uedo N, Watari J, Mori Y, Sakurai Y, Takanami Y, Nishimura A, Tatsumi T and Sakaki N: Randomised clinical trial: Efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 45:240–252. 2017. View Article : Google Scholar : PubMed/NCBI
22	Kagawa T, Iwamuro M, Ishikawa S, Ishida M, Kuraoka S, Sasaki K, Sakakihara I, Izumikawa K, Yamamoto K, Takahashi S, et al: Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. Aliment Pharmacol Ther. 44:583–591. 2016. View Article : Google Scholar : PubMed/NCBI
23	Ishimura N, Owada Y, Aimi M, Oshima T, Kamada T, Inoue K, Mikami H, Takeuchi T, Miwa H, Higuchi K, et al: No increase in gastric acid secretion in healthy Japanese over the past two decades. J Gastroenterol. 50:844–852. 2015. View Article : Google Scholar : PubMed/NCBI
24	Ishioka H, Mizuno M, Take S, Ishiki K, Nagahara Y, Yoshida T, Okada H, Yokota K and Oguma K: A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients. Digestion. 75:63–68. 2007. View Article : Google Scholar : PubMed/NCBI
25	De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, Stella F, Di Leo A, Russo F, Marangi S, et al: Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med. 144:94–100. 2006. View Article : Google Scholar : PubMed/NCBI
26	Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, Osato MS, El-Zaatari FA, Graham DY and Kwon DH: Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother. 44:2214–2216. 2000. View Article : Google Scholar : PubMed/NCBI
27	Katayama Y, Toyoda K, Kusano Y, Suda T, Adachi S, Terauchi I, Oka S, Takahashi M and Tamano M: Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed. Gut. 66:752–753. 2017. View Article : Google Scholar : PubMed/NCBI
28	Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K and Hattori M: Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol. 23:668–675. 2017. View Article : Google Scholar : PubMed/NCBI